Sernova Corp (SVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Sep 07, 2022: Sernova announces the appointment of Daniel Mahony, Ph.D. to its Board of Directors
Jun 15, 2022: Sernova to participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
May 18, 2022: Sernova and Evotec collaborate to develop cell therapy for diabetes
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like environment for the long-term survival and function of insulin producing islets for the treatment of diabetes. Sernova uses proprietary local immune protection technologies that protect therapeutic cells within the Cell Pouch from the attack of immune system. Its major pipeline products include human donor islets, microencapsulated islets; microencapsulated stem cell derived cells; corrected patient cells; allograft immune protected cells; and autograft thyroid cells. The company’s product portfolio addresses metabolic diseases such as insulin dependent diabetes, thyroid problems, and blood disorders such as hemophilia A and other diseases. Sernova is headquartered in London, Ontario, Canada.Sernova Corp Key Recent Developments
Dec 06, 2022: Sernova Corp. Announces CEO Succession Plan and Expanded Management TeamSep 07, 2022: Sernova announces the appointment of Daniel Mahony, Ph.D. to its Board of Directors
Jun 15, 2022: Sernova to participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
May 18, 2022: Sernova and Evotec collaborate to develop cell therapy for diabetes
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Sernova Corp - Key Facts
- Sernova Corp - Key Employees
- Sernova Corp - Key Employee Biographies
- Sernova Corp - Major Products and Services
- Sernova Corp - History
- Sernova Corp - Company Statement
- Sernova Corp - Locations And Subsidiaries
- Head Office
- Company Overview
- Sernova Corp - Business Description
- R&D Overview
- Sernova Corp - Corporate Strategy
- Sernova Corp - SWOT Analysis
- SWOT Analysis - Overview
- Sernova Corp - Strengths
- Sernova Corp - Weaknesses
- Sernova Corp - Opportunities
- Sernova Corp - Threats
- Sernova Corp - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Sernova Corp, Medical Equipment, Deals By Year, 2016 to YTD 2022
- Sernova Corp, Medical Equipment, Deals By Type, 2016 to YTD 2022
- Sernova Corp, Recent Deals Summary
- Dec 06, 2022: Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
- Sep 07, 2022: Sernova announces the appointment of Daniel Mahony, Ph.D. to its Board of Directors
- Jun 15, 2022: Sernova to participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
- May 18, 2022: Sernova and Evotec collaborate to develop cell therapy for diabetes
- May 05, 2022: Sernova to participate in Multiple U.S. Healthcare Investor Conferences
- Dec 14, 2021: Sernova appoints Christopher Barnes as Vice President, investor relations & grants options/DSUs
- Dec 02, 2021: Sernova announces appointment of executive chair to complement its management team
- Sep 29, 2021: Sernova engages New York-Based LifeSci Advisors as US investor relations partner
- Jun 30, 2021: Industry veteran Frank Shannon joins Sernova as VP Clinical Development and Regulatory Affairs
- May 04, 2021: Sernova announces the nomination of seasoned pharma executive Dr. Mohammad Azab to its board of directors
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Sernova Corp, Key Facts
- Sernova Corp, Key Employees
- Sernova Corp, Key Employee Biographies
- Sernova Corp, Major Products and Services
- Sernova Corp, History
- Sernova Corp, Key Competitors
- Sernova Corp, Ratios based on current share price
- Sernova Corp, Annual Ratios
- Sernova Corp, Interim Ratios
- Sernova Corp, Medical Equipment, Deals By Year, 2016 to YTD 2022
- Sernova Corp, Medical Equipment, Deals By Type, 2016 to YTD 2022
- Sernova Corp, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Sernova Corp, Performance Chart (2017 - 2021)
- Sernova Corp, Ratio Charts
- Sernova Corp, Medical Equipment, Deals By Year, 2016 to YTD 2022
- Sernova Corp, Medical Equipment, Deals by Type, 2016 to YTD 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Diamyd Medical AB
- ConjuChem LLC
- Generex Biotechnology Corp
- Alnara Pharmaceuticals Inc
- AstraZeneca Plc
- Semma Therapeutics Inc
- Sigilon Therapeutics Inc
- Diamyd Medical AB
- Alnara Pharmaceuticals Inc
- AstraZeneca Plc
- ConjuChem LLC
- Generex Biotechnology Corp
- Sigilon Therapeutics Inc
- Semma Therapeutics Inc
